Sarah Horvath
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sarah Horvath has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Carol S. Weisman
Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania
3 shared publications- Christine M. Leeper
Trauma and Transfusion Medicine Research Center, Department of Surgery University of Pittsburgh Pittsburgh Pennsylvania USA
3 shared publications - Douglas L. Leslie
Department of Public Health Sciences, College of Medicine, The Pennsylvania State University, Hershey, PA 17033, USA
3 shared publications - Philip C. Spinella
Trauma and Transfusion Medicine Research Center, Department of Surgery University of Pittsburgh Pittsburgh Pennsylvania USA
3 shared publications - Amy Zheng
Penn State College of Medicine, Hershey, Pennsylvania
2 shared publications - Cynthia H. Chuang
Penn State University College of Medicine, USA
2 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by Wiley in Pediatric Dermatology
Expert Recommendations for Use of Combined Oral Contraceptives in Preadolescent and Young Adolescent Patients With Acne Vulgaris
Acne vulgaris commonly presents in early adolescence with the onset of adrenarche. Treatments for acne in this age group typically mirror those in older adolescents. However, while combined oral contraceptives are an effective hormonal treatment for acne vulgaris in young women, the safety of using a systemic hormonal therapy in younger patients for the management of acne has not been established. Concerns include effects on pubertal development and weight, bone health, cancer risks, and psychiatric effects. This Pediatric Dermatology Research Alliance (PeDRA) consensus project convened a multidisciplinary work group to address these issues and, utilizing a modified Delphi process, to establish best practices regarding the use of combined oral contraceptives in patients under 16 years of age based on available evidence and expert opinion.
- 4 November 2026
- Published by Wiley in Pediatric Dermatology
Open AccessExpert Recommendations for Use of Combined Oral Contraceptives in Preadolescent and Young Adolescent Patients With Acne Vulgaris
Acne vulgaris commonly presents in early adolescence with the onset of adrenarche. Treatments for acne in this age group typically mirror those in older adolescents. However, while combined oral contraceptives are an effective hormonal treatment for acne vulgaris in young women, the safety of using a systemic hormonal therapy in younger patients for the management of acne has not been established. Concerns include effects on pubertal development and weight, bone health, cancer risks, and psychiatric effects. This Pediatric Dermatology Research Alliance (PeDRA) consensus project convened a multidisciplinary work group to address these issues and, utilizing a modified Delphi process, to establish best practices regarding the use of combined oral contraceptives in patients under 16 years of age based on available evidence and expert opinion.
- 1 September 2026
- Published by Taylor & Francis in Prehospital Emergency Care
- p. 1-12
RhD-Positive Transfusion in Females of Childbearing Potential in Hemorrhagic Shock: Risk, Reality, and Policy
Prehospital transfusion using Rhesus D antigen (RhD)-positive low-titer group O whole blood (LTOWB) or red blood cells is increasingly common when RhD-negative blood products are not available. However, concerns remain regarding D-alloimmunization in RhD-negative females of childbearing potential (FCPs), which could lead to future hemolytic disease of the fetus and newborn (HDFN). The magnitude of these risks, and their policy implications, have been the subject of recent investigation. To summarize the biological and epidemiological impacts and post-exposure management of RhD-positive transfusion in FCPs in hemorrhagic shock. This narrative review synthesizes the literature on the rate of D-alloimmunization, describes the results of modeling studies on the risk of HDFN following RhD-positive transfusion to FCPs, and examines epidemiologic studies estimating the HDFN risk at local, regional, and national levels. The D-alloimmunization risk mitigation strategies and current clinical guidelines are also reviewed. Several factors, including the low prevalence of RhD-negative individuals, the low rate of D-alloimmunization itself, potentially reduced pregnancy rates post-trauma, and advances in modern perinatal care decrease the overall risk of HDFN following the transfusion of RhD-positive blood products to FCPs in trauma. Some modeling studies estimated that fetal death due to anti-D-mediated HDFN would occur in fewer than 0.1% of FCPs exposed to RhD-positive blood products. Timely prehospital transfusion has demonstrated survival benefits for injured adults and children. National and regional epidemiological studies support the safety and utility of RhD-positive blood product use in emergency settings. Risk mitigation strategies include Rh immune globulin (RhIg) administration and structured post-exposure follow-up to detect alloimmunization and reduce potential future pregnancy harm. RhD-positive transfusion in FCPs during hemorrhagic shock when RhD-negative products are not available is supported by current evidence and ethical considerations. The risk of future HDFN is low and favorable perinatal outcomes can be achieved when the woman has access to modern prenatal health care. Risk may be further mitigated through post-exposure protocols. Prehospital transfusion policies should reflect this risk-benefit balance by enabling access to RhD-positive blood products for all trauma patients, including FCPs, if RhD-negative blood products are not available.
- 1 September 2026
- Published by Taylor & Francis in Prehospital Emergency Care
- p. 1-12
RhD-Positive Transfusion in Females of Childbearing Potential in Hemorrhagic Shock: Risk, Reality, and Policy
Prehospital transfusion using Rhesus D antigen (RhD)-positive low-titer group O whole blood (LTOWB) or red blood cells is increasingly common when RhD-negative blood products are not available. However, concerns remain regarding D-alloimmunization in RhD-negative females of childbearing potential (FCPs), which could lead to future hemolytic disease of the fetus and newborn (HDFN). The magnitude of these risks, and their policy implications, have been the subject of recent investigation. To summarize the biological and epidemiological impacts and post-exposure management of RhD-positive transfusion in FCPs in hemorrhagic shock. This narrative review synthesizes the literature on the rate of D-alloimmunization, describes the results of modeling studies on the risk of HDFN following RhD-positive transfusion to FCPs, and examines epidemiologic studies estimating the HDFN risk at local, regional, and national levels. The D-alloimmunization risk mitigation strategies and current clinical guidelines are also reviewed. Several factors, including the low prevalence of RhD-negative individuals, the low rate of D-alloimmunization itself, potentially reduced pregnancy rates post-trauma, and advances in modern perinatal care decrease the overall risk of HDFN following the transfusion of RhD-positive blood products to FCPs in trauma. Some modeling studies estimated that fetal death due to anti-D-mediated HDFN would occur in fewer than 0.1% of FCPs exposed to RhD-positive blood products. Timely prehospital transfusion has demonstrated survival benefits for injured adults and children. National and regional epidemiological studies support the safety and utility of RhD-positive blood product use in emergency settings. Risk mitigation strategies include Rh immune globulin (RhIg) administration and structured post-exposure follow-up to detect alloimmunization and reduce potential future pregnancy harm. RhD-positive transfusion in FCPs during hemorrhagic shock when RhD-negative products are not available is supported by current evidence and ethical considerations. The risk of future HDFN is low and favorable perinatal outcomes can be achieved when the woman has access to modern prenatal health care. Risk may be further mitigated through post-exposure protocols. Prehospital transfusion policies should reflect this risk-benefit balance by enabling access to RhD-positive blood products for all trauma patients, including FCPs, if RhD-negative blood products are not available.
- 1 July 2026
- Published by Elsevier in Women's Health Issues
- Vol. 36 (4) , 398-403
Rh Immunoglobulin Uptake With Opt-Out Versus Opt-In Policy in Patients Obtaining Abortion Care at Less Than 12 Weeks Gestation
- 1 July 2026
- Published by Elsevier in Women's Health Issues
- Vol. 36 (4) , 398-403
Rh Immunoglobulin Uptake With Opt-Out Versus Opt-In Policy in Patients Obtaining Abortion Care at Less Than 12 Weeks Gestation
- 30 April 2026
- Published by Elsevier in Women's Health Issues
- Vol. 36 (4) , 336-341
Who Is Still Paying Out-of-Pocket for Their IUDs Despite the ACA Contraceptive Coverage Requirement? Analysis of a Large National Cohort Using Claims Data
- 30 April 2026
- Published by Elsevier in Women's Health Issues
- Vol. 36 (4) , 336-341
Who Is Still Paying Out-of-Pocket for Their IUDs Despite the ACA Contraceptive Coverage Requirement? Analysis of a Large National Cohort Using Claims Data
- 23 April 2025
- Published by Elsevier in Women's Health Issues
- Vol. 35 (3) , 151-158
Contraception Coverage Policy in the United States: History and Current Challenges
- 23 April 2025
- Published by Elsevier in Women's Health Issues
- Vol. 35 (3) , 151-158
Contraception Coverage Policy in the United States: History and Current Challenges
- 27 February 2025
- Published by Elsevier in Contraception
- Vol. 146, 110858
Pennsylvania Medicaid policy and rural hospital implementation of immediate postpartum contraception
- 27 February 2025
- Published by Elsevier in Contraception
- Vol. 146, 110858
Pennsylvania Medicaid policy and rural hospital implementation of immediate postpartum contraception
- 27 January 2025
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 52 (2) , 197-205
Challenges to Family Planning Education and Future Workforce Effects
- 27 January 2025
- Published by Elsevier in Obstetrics and Gynecology Clinics of North America
- Vol. 52 (2) , 197-205
Challenges to Family Planning Education and Future Workforce Effects
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (2) , e240122
A Lexicon for First-Trimester US: Society of Radiologists in Ultrasound Consensus Conference Recommendations
The Society of Radiologists in Ultrasound First-Trimester US Lexicon recommends well-defined, scientific, and specific terminology to communicate clearly across disciplines, minimize bias and harm, and respect patient preferences.
- 1 August 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 312 (2) , e240122
A Lexicon for First-Trimester US: Society of Radiologists in Ultrasound Consensus Conference Recommendations
The Society of Radiologists in Ultrasound First-Trimester US Lexicon recommends well-defined, scientific, and specific terminology to communicate clearly across disciplines, minimize bias and harm, and respect patient preferences.
- Open Access
- 23 July 2024
- Published by Wiley in Transfusion
- Vol. 64 (9) , 1784-1790
A review of attitudes to urgent RhD‐positive transfusions in female patients and the risk for hemolytic disease of the fetus and newborn
- 23 July 2024
- Published by Wiley in Transfusion
- Vol. 64 (9) , 1784-1790
Open AccessA review of attitudes to urgent RhD‐positive transfusions in female patients and the risk for hemolytic disease of the fetus and newborn
- 19 June 2024
- Published by Elsevier in Contraception
- Vol. 139, 110530
Economic analysis of foregoing Rh immunoglobulin for bleeding in pregnancy <12 weeks gestation
- 19 June 2024
- Published by Elsevier in Contraception
- Vol. 139, 110530
Economic analysis of foregoing Rh immunoglobulin for bleeding in pregnancy <12 weeks gestation